A Phase 2 interventional study of AKB-6548 and Placebo in Anemia and Kidney Disease, sponsored by Akebia Therapeutics. Completed at 28 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-01.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 13th largest by enrollment, is the only one that started in 2011, is one of 8 in phase 2, and was the 2nd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2011.
This study's enrollment of 93 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 9 in phase 2, and was the 2nd registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the dose response (efficacy), pharmacodynamic response, pharmacokinetics, safety, and tolerability of orally administered AKB-6548 in pre-dialysis participants with anemia with repeat dosing for 42 days.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AKB-6548
Drug: AKB-6548
Drug: AKB-6548
Drug: AKB-6548
Drug: Placebo
oral dose administered once daily for 42 days
oral Placebo administered once daily for 42 days
Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6)
Absolute change from Baseline was calculated as the Week 6 (end of treatment) value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing. If there was only one measurement prior to dosing, this measurement served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.
Time frame: Baseline, Week 6
Change From Baseline in Hgb at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Hematocrit (HCT) at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated HCT concentration increased.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Red Blood Cell (RBC) Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated RBC count increased.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Absolute Reticulocyte Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte count increased.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Reticulocyte Hgb Content at Week 6
Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte Hgb content increased.
Time frame: Baseline, Week 6
Maximum Change From Baseline in Hgb
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.
Time frame: Baseline; up to Week 8
Maximum Change From Baseline in HCT
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that HCT concentration increased.
Time frame: Baseline; up to Week 8
Maximum Change From Baseline in RBC Count
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that RBC count increased.
Time frame: Baseline; up to Week 8
Maximum Change in Absolute Reticulocyte Count From Baseline
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline absolute reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that reticulocyte count increased.
Time frame: Baseline; up to Week 8
Number of Participants With Absolute Change From Baseline in Hgb ≥ 0.4, 0.6, 0.8, and 1.0 g/dL at the End of Dosing Period
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Up to Week 6 (End of the Dosing Period)
Number of Participants With Change From Baseline in Hgb ≥5.0, 7.5, and 10.0% by the End of Dosing Period
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Up to Week 6 (End of The Dosing Period)
Number of Participants With Change From Baseline in HCT ≥5.0, 7.5, and 10.0% by the End of Dosing Period
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Up to Week 6 (End of The Dosing Period)
Number of Participants With Change From Baseline in RBC Count ≥5.0, 7.5, and 10.0% by the End of Dosing Period
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Up to Week 6 (End of The Dosing Period)
Number of Participants With Change From Baseline in Reticulocyte Count ≥6000, 12000, and 18000 Cells/uL by the End of Dosing Period
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline reticulocytes count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Up to Week 6 (End of The Dosing Period)
Change From Baseline in Total Iron at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline total iron was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Unsaturated Iron Binding Capacity at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Unsaturated Iron Binding Capacity was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Iron Saturation at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron saturation was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Ferritin at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up (up to Week 8)
Change From Baseline in Erythropoietin at Week 2, Week 6, and Follow-up Visit (up to Week 8)
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline erythropoietin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 2, Week 6, Follow-up Visit (up to Week 8)
Change From Baseline in Hepcidin at Week 6
Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline hepcidin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
Time frame: Baseline, Week 6
Mean Plasma Vadadustat Concentrations on Week 2 and Week 4
Plasma samples were collected for the analysis.
Time frame: Week 2: Pre-dose and post-dose; Week 4: Pre-dose
Mean Plasma Vadadustat Acyl-Glucuronide Concentrations on Week 2 and Week 4
Plasma samples were collected for the analysis.
Time frame: Week 2: Pre-dose; Week 4: Pre-dose
Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter
Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Number of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. Clinical significance is determined by the investigator. The investigator was responsible for reviewing laboratory results for clinical significance.
Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).
Time frame: Baseline, Week 6
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Parameters assessed for laboratory values included hematology, serum chemistry, C-reactive protein, DHEA-S, VEGF, and cystatin C. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)
| Milestone | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Started | 18 | 18 | 17 | 19 | 19 |
| Completed | 16 | 15 | 17 | 18 | 18 |
| Not completed | 2 | 3 | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal of informed consent | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant given aranesp injection | 1 | 0 | 0 | 0 | 0 |
Absolute change from Baseline was calculated as the Week 6 (end of treatment) value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing. If there was only one measurement prior to dosing, this measurement served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.
| Grams per deciliter (g/dL) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 9.46 ± 0.792 | 9.93 ± 0.643 | 9.86 ± 0.606 | 9.67 ± 0.796 | 9.83 ± 0.677 |
| Change from Baseline at Week 6 | 0.77 ± 0.665 | 0.73 ± 0.623 | 1.25 ± 0.644 | 1.43 ± 0.668 | -0.03 ± 0.649 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.
| g/dL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 9.46 ± 0.792 | 9.93 ± 0.643 | 9.86 ± 0.606 | 9.67 ± 0.796 | 9.83 ± 0.677 |
| Change from Baseline to Week 1 | 0.06 ± 0.559 | -0.12 ± 0.452 | 0.28 ± 0.439 | 0.29 ± 0.622 | 0.04 ± 0.531 |
| Change from Baseline to Week 2 | 0.16 ± 0.575 | 0.00 ± 0.590 | 0.54 ± 0.586 | 0.53 ± 0.455 | 0.14 ± 0.654 |
| Change from Baseline to Week 4 | 0.54 ± 0.659 | 0.36 ± 0.605 | 0.85 ± 0.650 | 1.06 ± 0.900 | 0.08 ± 0.613 |
| Change from Baseline to Week 6 | 0.77 ± 0.665 | 0.73 ± 0.623 | 1.25 ± 0.644 | 1.43 ± 0.668 | -0.03 ± 0.649 |
| Change from Baseline to Follow-up Visit (up to Week 8) | 0.78 ± 0.685 | 0.40 ± 0.553 | 1.04 ± 0.848 | 1.01 ± 0.872 | 0.06 ± 0.877 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated HCT concentration increased.
| Percentage of red blood cells in blood | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 29.0 ± 2.57 | 29.6 ± 2.45 | 30.4 ± 2.41 | 29.6 ± 3.68 | 29.8 ± 1.96 |
| Change from Baseline to Week 1 | 0.5 ± 2.28 | 0.2 ± 1.87 | 1.2 ± 1.25 | 1.6 ± 2.65 | 0.2 ± 1.70 |
| Change from Baseline to Week 2 | 0.2 ± 2.46 | 0.1 ± 1.59 | 1.6 ± 2.33 | 1.5 ± 2.04 | 0.3 ± 2.06 |
| Change from Baseline to Week 4 | 1.7 ± 2.37 | 0.6 ± 1.67 | 3.1 ± 2.59 | 3.4 ± 3.52 | 0.1 ± 2.34 |
| Change from Baseline to Week 6 | 1.8 ± 2.71 | 2.1 ± 2.46 | 3.4 ± 2.47 | 4.3 ± 2.74 | -0.4 ± 2.40 |
| Change from Baseline to Follow-up Visit (up to Week 8) | 1.9 ± 2.30 | 0.7 ± 1.90 | 2.4 ± 2.62 | 2.8 ± 3.44 | 0.0 ± 2.78 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated RBC count increased.
| 10^6 cells/microliter (10^6 cells/μL) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 3.21 ± 0.415 | 3.38 ± 0.286 | 3.37 ± 0.286 | 3.25 ± 0.366 | 3.34 ± 0.463 |
| Change from Baseline to Week 1 | -0.01 ± 0.185 | -0.07 ± 0.178 | 0.09 ± 0.187 | 0.04 ± 0.227 | -0.02 ± 0.231 |
| Change from Baseline to Week 2 | 0.02 ± 0.183 | -0.05 ± 0.186 | 0.14 ± 0.229 | 0.11 ± 0.172 | 0.03 ± 0.281 |
| Change from Baseline to Week 4 | 0.16 ± 0.213 | 0.01 ± 0.202 | 0.26 ± 0.251 | 0.27 ± 0.294 | 0.02 ± 0.229 |
| Change from Baseline to Week 6 | 0.17 ± 0.243 | 0.18 ± 0.273 | 0.39 ± 0.252 | 0.41 ± 0.243 | -0.02 ± 0.223 |
| Change from Baseline to Follow-up Visit (up to Week 8) | 0.24 ± 0.242 | 0.06 ± 0.199 | 0.30 ± 0.248 | 0.26 ± 0.273 | 0.01 ± 0.290 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte count increased.
| 10^6 cells/μL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 0.0766 ± 0.02855 | 0.0569 ± 0.01891 | 0.0811 ± 0.01993 | 0.0674 ± 0.02715 | 0.0700 ± 0.03319 |
| Change from Baseline to Week 1 | 0.0022 ± 0.01279 | 0.0134 ± 0.01733 | 0.0259 ± 0.02223 | 0.0289 ± 0.03152 | 0.0010 ± 0.01677 |
| Change from Baseline to Week 2 | 0.0012 ± 0.01505 | 0.0196 ± 0.01919 | 0.0346 ± 0.01997 | 0.0292 ± 0.01625 | -0.0015 ± 0.01091 |
| Change from Baseline to Week 4 | 0.0029 ± 0.01181 | 0.0128 ± 0.01586 | 0.0234 ± 0.02685 | 0.0206 ± 0.02369 | -0.0023 ± 0.01636 |
| Change from Baseline to Week 6 | -0.0020 ± 0.01736 | 0.0116 ± 0.02390 | 0.0061 ± 0.02217 | 0.0047 ± 0.02639 | -0.0004 ± 0.01788 |
| Change from Baseline to Follow-up Visit (up to Week 8) | -0.0042 ± 0.01900 | 0.0015 ± 0.02616 | -0.0152 ± 0.01467 | -0.0119 ± 0.02494 | -0.0035 ± 0.01522 |
Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte Hgb content increased.
| Picogram | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 31.02 ± 2.945 | 31.44 ± 2.257 | 30.26 ± 2.605 | 31.54 ± 2.575 | 30.73 ± 2.634 |
| Change From Baseline at Week 6 | 0.37 ± 0.971 | 0.29 ± 0.742 | 0.06 ± 0.964 | 0.15 ± 1.214 | 0.03 ± 1.104 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.
| g/dL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 9.46 ± 0.792 | 9.93 ± 0.643 | 9.86 ± 0.606 | 9.67 ± 0.796 | 9.83 ± 0.677 |
| Maximum change from Baseline (up to Week 8) | 1.04 ± 0.585 | 0.82 ± 0.581 | 1.44 ± 0.675 | 1.54 ± 0.911 | 0.59 ± 0.568 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that HCT concentration increased.
| Percentage of red blood cells | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 29.0 ± 2.57 | 29.6 ± 2.45 | 30.4 ± 2.41 | 29.6 ± 3.68 | 29.8 ± 1.96 |
| Maximum change from Baseline (up to Week 8) | 2.94 ± 2.578 | 2.56 ± 2.097 | 4.43 ± 2.277 | 4.84 ± 3.452 | 1.89 ± 1.729 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that RBC count increased.
| 10^6 cells/μL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 3.21 ± 0.415 | 3.38 ± 0.286 | 3.37 ± 0.286 | 3.25 ± 0.366 | 3.34 ± 0.463 |
| Maximum change from Baseline (up to Week 8) | 0.31 ± 0.210 | 0.22 ± 0.239 | 0.44 ± 0.249 | 0.44 ± 0.291 | 0.18 ± 0.183 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline absolute reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that reticulocyte count increased.
| 10^6 cells/μL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 0.0766 ± 0.02855 | 0.0569 ± 0.01891 | 0.0811 ± 0.01993 | 0.0674 ± 0.02715 | 0.0700 ± 0.03319 |
| Maximum Change from Baseline (up to Week 8) | 0.013 ± 0.0145 | 0.028 ± 0.0184 | 0.040 ± 0.0200 | 0.042 ± 0.0263 | 0.011 ± 0.0129 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Change from Baseline in Hgb ≥0.4 g/dL | 3 | 2 | 2 | 1 | 2 |
| Change from Baseline in Hgb ≥0.6 g/dL | 3 | 2 | 0 | 1 | 0 |
| Change from Baseline in Hgb ≥0.8 g/dL | 3 | 2 | 3 | 1 | 0 |
| Change from Baseline in Hgb ≥1.0 g/dL | 5 | 6 | 11 | 14 | 2 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| % Change from Baseline in Hgb ≥5% | 4 | 3 | 1 | 1 | 2 |
| % Change from Baseline in Hgb ≥7.5% | 4 | 3 | 3 | 1 | 0 |
| % Change from Baseline in Hgb ≥10.0% | 5 | 5 | 11 | 14 | 2 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| % Change from Baseline in HCT ≥5% | 4 | 3 | 2 | 0 | 1 |
| % Change from Baseline in HCT ≥7.5% | 1 | 0 | 0 | 4 | 1 |
| % Change from Baseline in HCT ≥10.0% | 4 | 6 | 9 | 11 | 1 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| % Change from Baseline in RBCs ≥5% | 4 | 3 | 2 | 3 | 1 |
| % Change from Baseline in RBCs ≥7.5% | 2 | 2 | 3 | 1 | 0 |
| % Change from Baseline in RBCs ≥10.0% | 2 | 4 | 8 | 11 | 1 |
Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline reticulocytes count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Change from Baseline in Reticulocytes ≥6000 cells/uL | 1 | 1 | 4 | 2 | 3 |
| Change from Baseline in Reticulocytes ≥12000 cells/uL | 1 | 3 | 0 | 3 | 1 |
| Change from Baseline in Reticulocytes ≥18000 cells/uL | 2 | 5 | 4 | 5 | 2 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline total iron was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Micrograms per deciliter (µg/dL) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 66.0 ± 18.68 | 77.8 ± 22.47 | 76.1 ± 32.01 | 60.7 ± 20.51 | 67.6 ± 21.12 |
| Change from Baseline to Week 2 | -1.8 ± 15.87 | -3.7 ± 18.96 | 10.9 ± 22.93 | 10.4 ± 24.54 | -4.1 ± 18.55 |
| Change from Baseline to Week 4 | -1.5 ± 21.62 | 4.0 ± 16.36 | -1.6 ± 20.49 | 13.2 ± 24.18 | -2.2 ± 20.47 |
| Change from Baseline to Week 6 | 3.6 ± 23.26 | 2.8 ± 15.44 | 3.7 ± 25.19 | 0.7 ± 16.54 | -8.6 ± 25.81 |
| Change from Baseline to Follow-up Visit (up to Week 8) | -7.4 ± 19.25 | -7.5 ± 22.90 | 0.9 ± 31.90 | 6.2 ± 18.50 | 3.4 ± 16.05 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Unsaturated Iron Binding Capacity was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| µg/dL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 153.4 ± 34.26 | 168.0 ± 52.46 | 173.1 ± 56.48 | 171.2 ± 38.77 | 175.5 ± 33.14 |
| Change from Baseline to Week 2 | 10.9 ± 18.78 | 22.4 ± 19.52 | 17.2 ± 32.16 | 21.3 ± 27.40 | -1.5 ± 20.61 |
| Change from Baseline to Week 4 | 14.4 ± 25.96 | 26.1 ± 22.30 | 31.5 ± 27.08 | 37.4 ± 20.16 | -3.7 ± 27.89 |
| Change from Baseline to Week 6 | 15.3 ± 30.52 | 34.0 ± 25.62 | 29.3 ± 16.06 | 49.6 ± 26.50 | -1.3 ± 17.81 |
| Change from Baseline to Follow-up Visit (up to Week 8) | 15.1 ± 30.46 | 16.2 ± 22.74 | -0.7 ± 23.06 | 3.9 ± 42.20 | 0.7 ± 20.72 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron saturation was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Percentage of saturation | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 30.4 ± 7.56 | 32.4 ± 9.82 | 31.4 ± 13.35 | 26.5 ± 10.17 | 27.7 ± 6.60 |
| Change from Baseline to Week 2 | -1.5 ± 6.26 | -3.8 ± 7.34 | 1.4 ± 9.15 | 0.6 ± 8.81 | -0.9 ± 7.86 |
| Change from Baseline to Week 4 | -1.9 ± 8.10 | -2.3 ± 7.00 | -3.7 ± 7.91 | -0.2 ± 6.52 | -0.2 ± 8.65 |
| Change from Baseline to Week 6 | -0.3 ± 9.24 | -3.8 ± 6.36 | -2.3 ± 7.69 | -4.6 ± 6.44 | -2.1 ± 9.09 |
| Change from Baseline to Follow-up Visit (up to Week 8) | -4.1 ± 7.08 | -3.9 ± 8.90 | 0.5 ± 9.94 | 1.6 ± 9.27 | 1.2 ± 5.80 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| µg/dL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 219.4 ± 39.39 | 245.8 ± 54.61 | 249.2 ± 45.29 | 231.8 ± 36.19 | 243.1 ± 40.02 |
| Change from Baseline to Week 2 | 9.2 ± 16.34 | 18.7 ± 18.09 | 28.1 ± 22.32 | 31.7 ± 28.73 | -5.5 ± 22.51 |
| Change from Baseline to Week 4 | 12.9 ± 24.97 | 30.1 ± 16.20 | 29.9 ± 24.08 | 50.5 ± 28.64 | -5.9 ± 17.96 |
| Change from Baseline to Week 6 | 18.8 ± 28.81 | 36.8 ± 27.76 | 33.0 ± 28.54 | 50.3 ± 27.80 | -9.9 ± 25.70 |
| Change from Baseline to Follow-up Visit (up to Week 8) | 7.8 ± 34.88 | 8.7 ± 18.15 | 0.2 ± 25.82 | 10.2 ± 30.15 | 4.1 ± 23.83 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| Nanograms per milliliter (ng/mL) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 349.5 ± 226.27 | 245.8 ± 215.18 | 332.3 ± 330.81 | 240.2 ± 142.10 | 200.8 ± 115.99 |
| Change from Baseline to Week 2 | -66.0 ± 67.72 | -41.7 ± 53.18 | -72.0 ± 75.89 | -58.9 ± 54.72 | -12.9 ± 35.49 |
| Change from Baseline to Week 4 | -69.8 ± 101.67 | -48.7 ± 63.08 | -89.6 ± 138.80 | -80.6 ± 64.50 | -20.5 ± 39.24 |
| Change from Baseline to Week 6 | -65.5 ± 115.89 | -59.4 ± 58.76 | -88.9 ± 64.66 | -86.6 ± 62.73 | -19.6 ± 41.72 |
| Change from Baseline to Follow-up Visit (up to Week 8) | -50.4 ± 91.22 | -37.7 ± 73.31 | -86.1 ± 67.75 | -27.4 ± 107.42 | -20.2 ± 39.35 |
Change from Baseline was calculated as the visit value minus the Baseline value. Baseline erythropoietin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| ng/mL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 18.011 ± 56.3608 | 4.339 ± 4.1462 | 7.287 ± 8.8333 | 8.826 ± 10.2773 | 6.963 ± 14.1425 |
| Change from Baseline to Week 2 | -3.538 ± 20.3172 | 0.606 ± 3.2070 | 1.142 ± 11.8961 | -2.483 ± 9.5483 | -0.850 ± 9.3370 |
| Change from Baseline to Week 6 | -3.050 ± 15.1756 | -1.013 ± 3.9836 | -3.329 ± 5.9821 | -0.372 ± 14.4615 | -1.492 ± 10.1597 |
| Change from Baseline to Follow-up Visit (up to Week 8) | -3.853 ± 15.1335 | -0.563 ± 5.5372 | -2.061 ± 6.2689 | -4.844 ± 9.4601 | -2.650 ± 8.2146 |
Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline hepcidin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.
| ng/mL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline | 326.35 ± 222.037 | 241.03 ± 158.871 | 242.51 ± 117.326 | 282.75 ± 239.266 | 258.29 ± 144.115 |
| Change from Baseline at Week 6 | -28.64 ± 185.263 | -90.91 ± 106.826 | -85.01 ± 45.864 | -144.90 ± 184.640 | -32.54 ± 103.937 |
Plasma samples were collected for the analysis.
| μg/mL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg |
|---|---|---|---|---|
| Week 2 Pre-Dose | 4358.28 ± 2549.623 | 6640.04 ± 5141.484 | 10791.79 ± 9823.143 | 12443.17 ± 17095.495 |
| Week 2 Post-Dose | 17036.82 ± 8035.308 | 21371.63 ± 8664.304 | 39892.00 ± 19891.284 | 41656.11 ± 20002.713 |
| Week 4 Pre-Dose | 4698.21 ± 3520.520 | 7884.56 ± 5517.132 | 14274.80 ± 16141.439 | 17700.17 ± 19532.648 |
Plasma samples were collected for the analysis.
| μg/mL | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg |
|---|---|---|---|---|
| Week 2 Pre-Dose | 1848.4 ± 979.73 | 2708.5 ± 1879.02 | 5900.1 ± 8309.24 | 6425.0 ± 7214.67 |
| Week 4 Pre-Dose | 1999.3 ± 1427.74 | 2687.5 ± 2027.63 | 6866.9 ± 9247.39 | 7960.8 ± 6643.98 |
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| TEAEs | 9 | 6 | 8 | 11 | 11 |
| SAEs | 2 | 3 | 1 | 1 | 1 |
Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter | 0 | 0 | 0 | 0 | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. Clinical significance is determined by the investigator. The investigator was responsible for reviewing laboratory results for clinical significance.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 | 0 |
A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).
| Milliseconds | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Baseline PR Interval | 156.7 ± 46.90 | 174.6 ± 40.89 | 172.8 ± 51.06 | 187.8 ± 45.72 | 175.8 ± 31.82 |
| Change from Baseline PR Interval | -0.8 ± 22.95 | 2.2 ± 12.37 | 11.4 ± 29.72 | -11.7 ± 63.75 | -0.4 ± 13.07 |
| Baseline QRS Duration | 94.9 ± 21.35 | 113.8 ± 37.57 | 97.1 ± 28.07 | 94.5 ± 12.65 | 94.6 ± 12.52 |
| Change from Baseline QRS Duration | 4.1 ± 9.52 | 2.0 ± 13.29 | -1.3 ± 7.23 | 1.4 ± 10.28 | -1.6 ± 5.33 |
| Baseline QT Interval | 412.0 ± 41.59 | 421.4 ± 46.58 | 419.0 ± 44.97 | 406.9 ± 42.97 | 419.1 ± 40.10 |
| Change from Baseline QT Interval | 3.8 ± 24.78 | 7.8 ± 25.33 | -1.6 ± 19.83 | 4.5 ± 24.10 | 11.0 ± 23.35 |
| Baseline QTC Interval | 424.9 ± 27.70 | 436.3 ± 37.56 | 445.1 ± 36.10 | 427.6 ± 23.60 | 435.6 ± 17.90 |
| Change from Baseline QTC Interval | 5.1 ± 14.33 | 3.6 ± 17.65 | -5.8 ± 20.70 | -1.6 ± 16.74 | 3.3 ± 21.46 |
Parameters assessed for laboratory values included hematology, serum chemistry, C-reactive protein, DHEA-S, VEGF, and cystatin C. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values | 0 | 0 | 0 | 0 | 0 |
Collected over Up to Week 8 (Follow-up Visit 2 weeks after last dose). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AKB-6548 240 mg | 0/18 (0%) | 2/18 (11.1%) | 9/18 (50%) |
| AKB-6548 370 mg | 1/18 (5.6%) | 3/18 (16.7%) | 5/18 (27.8%) |
| AKB-6548 500 mg | 0/17 (0%) | 1/17 (5.9%) | 8/17 (47.1%) |
| AKB-6548 630 mg | 0/19 (0%) | 1/19 (5.3%) | 11/19 (57.9%) |
| Placebo | 0/19 (0%) | 1/19 (5.3%) | 11/19 (57.9%) |
| Event | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/18 | 0/18 | 1/17 | 0/19 | 0/19 |
| Coronary artery diseaseCardiac disorders | 0/18 | 1/18 | 0/17 | 0/19 | 0/19 |
| GastroenteritisInfections and infestations | 1/18 | 0/18 | 0/17 | 0/19 | 0/19 |
| AzotaemiaRenal and urinary disorders | 0/18 | 1/18 | 0/17 | 0/19 | 0/19 |
| Cardiac pacemaker replacementCardiac disorders | 1/18 | 0/18 | 0/17 | 0/19 | 0/19 |
| Hypertensive crisisVascular disorders | 0/18 | 1/18 | 0/17 | 0/19 | 0/19 |
| Fluid overloadMetabolism and nutrition disorders | 0/18 | 0/18 | 0/17 | 0/19 | 1/19 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/18 | 0/18 | 0/17 | 1/19 | 0/19 |
| Event | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo |
|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 1/18 | 0/18 | 3/17 | 0/19 | 1/19 |
| HypertensionVascular disorders | 0/18 | 0/18 | 0/17 | 2/19 | 3/19 |
| NauseaGastrointestinal disorders | 1/18 | 1/18 | 2/17 | 1/19 | 2/19 |
| Urinary tract infectionInfections and infestations | 2/18 | 0/18 | 1/17 | 1/19 | 0/19 |
| HeadacheNervous system disorders | 2/18 | 0/18 | 0/17 | 0/19 | 0/19 |
| AnaemiaBlood and lymphatic system disorders | 0/18 | 0/18 | 0/17 | 0/19 | 2/19 |
| HypotensionVascular disorders | 0/18 | 0/18 | 0/17 | 0/19 | 2/19 |
| ConstipationGastrointestinal disorders | 1/18 | 1/18 | 1/17 | 1/19 | 0/19 |
| DiarrhoeaGastrointestinal disorders | 0/18 | 1/18 | 1/17 | 0/19 | 0/19 |
| Frequent bowel movementsGastrointestinal disorders | 0/18 | 0/18 | 1/17 | 0/19 | 0/19 |
Intent-to-treat (ITT) Population: All randomized participants who received at least one dose of study medication.
| Age, Continuous(Years) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 64.2 ± 12.17 | 68.9 ± 7.84 | 64.7 ± 9.47 | 64.9 ± 8.79 | 64.9 ± 9.97 | 65.5 ± 9.69 |
| Sex: Female, Male(Participants) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 9 | 7 | 13 | 7 | 12 | 48 |
| Male | 9 | 11 | 4 | 12 | 7 | 43 |
| Ethnicity (NIH/OMB)(Participants) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 4 | 4 | 5 | 24 |
| Not Hispanic or Latino | 11 | 14 | 13 | 15 | 14 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 | 2 |
| Black or African American | 6 | 4 | 4 | 7 | 3 | 24 |
| White | 10 | 13 | 13 | 9 | 14 | 59 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 1 | 1 | 4 |
| CKD stage(Participants) | AKB-6548 240 mg | AKB-6548 370 mg | AKB-6548 500 mg | AKB-6548 630 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Stage 3 | 5 | 4 | 4 | 5 | 5 | 23 |
| Stage 4 | 13 | 14 | 13 | 14 | 14 | 68 |
Plan to share: No
Ran from Jun 2011 to primary completion in Feb 2012, 8 months.
Results were first posted in Jul 2022, 10 years 4 months after primary completion. A results delay was requested in Oct 2012.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 8 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat